96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,400 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-004919-36-AT
(EUCTR)
20/05/200910/11/2008A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseA Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease Crohn's disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: ABT-874
Product Code: ABT-874
Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0
AbbottNULLNot RecruitingFemale: yes
Male: yes
225Phase 2Denmark;Austria;Sweden
2EUCTR2008-004919-36-SE
(EUCTR)
11/03/200911/12/2008A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseA Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease Crohn's disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: ABT-874
Product Code: ABT-874
INN or Proposed INN: None
Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0
AbbottNULLNot RecruitingFemale: yes
Male: yes
225Phase 2Denmark;Austria;Sweden
3EUCTR2008-004919-36-DK
(EUCTR)
23/01/200918/12/2008A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseA Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease Crohn's disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: ABT-874
Product Code: ABT-874
INN or Proposed INN: None
Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0
AbbottNULLNot RecruitingFemale: yes
Male: yes
225Phase 2Denmark;Austria;Sweden
4EUCTR2008-004919-36-BE
(EUCTR)
20/01/200914/11/2008A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseA Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease Crohn's disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: ABT-874
Product Code: ABT-874
INN or Proposed INN: None
Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0
AbbottNULLNot RecruitingFemale: yes
Male: yes
225Phase 2Belgium;Denmark;Austria;Sweden
5NCT00007163
(ClinicalTrials.gov)
December 20009/12/2000Monoclonal Antibody Treatment of Crohn's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Levels of Subcutaneously Administered Human Monoclonal Antibody to Interleukin-12 (J695) in Patients With Active Crohn's DiseaseCrohn's DiseaseDrug: J695National Institute of Allergy and Infectious Diseases (NIAID)NULLCompletedN/AN/ABoth40Phase 1United States